PM Stock Dropped Nearly 5% in a Single Day — and the FDA Is the Reason

The situation Philip Morris International is in going into April 2026 is almost paradoxical. The market is punishing a company that has invested over $16 billion since 2008 in an attempt to shift away from cigarettes. The company built IQOS heated tobacco devices, acquired Swedish Match for its ZYN nicotine pouches, and reorganized its entire identity around a “smoke-free future.” This is because the company’s smoke-free strategy is encountering regulatory resistance. In a single session on April 1, the stock fell by almost 5%. The FDA is moving slowly, not because of a poor earnings report or a decline in demand. For a business that has, by all accounts, been performing well, this is an odd kind of trouble.

Just a few weeks ago, in late February, PM stock reached a 52-week high of $191.30; it is currently trading at $157.49 on the NYSE. Depending on how you interpret the regulatory situation, the pullback has been severe and either entirely justified or a little excessive. The company hasn’t failed. Revenue for the fourth quarter of 2025 was $10.36 billion, up almost 7% from the previous year. In seven of the previous eight quarters, the company’s earnings exceeded forecasts.

Philip Morris International Inc.

A few years ago, this milestone would have seemed unattainable, but today, smoke-free products make up 41.5% of total net revenues. ZYN, a white, tobacco-leaf-free nicotine pouch that comes in little round cans, shipped 794 million units in the US alone in 2025, a 37% increase from the previous year. About 70% of the nicotine pouch market in the US is controlled by Philip Morris. The transition story is succeeding in terms of volume, share, and consumer adoption.

Then, with hesitation, the FDA intervened. On April 1, there were rumors that the agency was slowing down its fast-track review procedure for nicotine pouches due to worries about youth access and the scant scientific data supporting their safety profile for teenagers. The ZYN Ultra application, which would enable Philip Morris to market stronger nicotine products to adult consumers who presently purchase from rival companies, is currently in a regulatory pilot program with an unclear approval timeline. During the Q4 earnings call, CEO Jacek Olczak acknowledged the situation while using tactful language that made the limitation evident. After stating that the business was prepared for launch, he promised not to “fortune tell” about the FDA’s timing. That’s CEO jargon for “we really don’t know when this gets resolved.”

This creates a genuine product gap that is important to comprehend. At the moment, ZYN works in the nicotine strength range of three to six milligrams. The higher-strength market is precisely where Altria faces competition! The PLUS product has been distributed nationwide; however, Philip Morris is unable to enter this market until regulatory approval is obtained. Even when the core numbers appear good, investors get anxious when they see a company with 70% market share unable to service a growing segment of its own category due to a pending application. Whether the FDA’s cautious stance on nicotine pouches will resolve rather quickly or solidify into something structural is still up in the air. The share price is directly reflecting this uncertainty.

At the same time, Philip Morris is under pressure from a larger industry context. On April 1, Japan enacted new tobacco tax increases, which increased costs for the company’s traditional combustible business in one of its main markets. Although insider sales by themselves are rarely the whole story, insider selling—reportedly worth about $29 million in recent transactions—has contributed to the cautious atmosphere. The Williams %R signal indicates oversold conditions, the RSI is at 41, and the MACD is in negative territory. The fundamental narrative is largely supported by the technical picture: a stock that was priced for a clear regulatory runway has encountered friction and is adjusting appropriately.

The size of what Philip Morris has already created is what makes this situation intriguing rather than merely alarming. Its smoke-free products are currently being used by 43 million adult consumers in 105 countries. The nicotine pouch market in Ukraine alone is growing by 20% annually, and Philip Morris is investing $10 million there this year to expand its ZYN line, first importing from Sweden before expanding production geographically. These are not the signs of a failing product line. They represent the footprints of a product line that is in the process of becoming truly global, navigating the kind of regulatory growing pains that arise when a new category develops more quickly than government frameworks were intended to accommodate.

The next actual test is on April 22. The first quarterly report under the company’s recently reorganized three-segment framework—International Smoke-Free, International Combustibles, and US—as well as Q1 2026 earnings are released at that time. Investors will be able to see ZYN’s true margin profile for the first time thanks to the more transparent US disclosure, as it will no longer be combined with larger regional figures. Investor patience will be put to the test if the US segment demonstrates that the promotional spending drag from Q4 continues into Q1. For Q1 adjusted EPS, the consensus estimate is $1.82. Most of the time, the business has passed that test. The question of whether the regulatory overhang affects the reaction in any way remains unanswered.